Evidence map›Paper›PMID 34963828›Full record

ArticleCureus2021

Determinants for Acceptance of COVID-19 Vaccine in Nigeria.

Ugochukwu A Eze, Kingsley I Ndoh, Babalola A Ibisola, Chinemerem D Onwuliri, Adenekan Osiyemi, Nnamdi Ude, Amalachukwu A Chime, Eric O Ogbor, Adegboyega O Alao, Ashiru Abdullahi

Open access · diamondAbstract read
In one paragraph

Article in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 44 citations in OpenAlex.

  1. Trends and spatial distribution of pediatric second-dose COVID-19 vaccination coverage: a temporal analysis, Brazil, 2022-2023.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Views of Nigerian civil servants about compulsory COVID-19 vaccination: A qualitative study.African journal of primary health care & family medicine · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. COVID-19 vaccine hesitancy in Africa: a scoping review.Global health research and policy · 2022
    Article
  17. Addressing vaccine hesitancy and resistance for COVID-19 vaccines.International journal of nursing studies · 2022
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Ugochukwu A EzeDepartment of Ophthalmology, Federal Medical Centre, Asaba, NGA.
Kingsley I NdohDepartment of Global Health, University of Washington, Seattle, USA.
Babalola A IbisolaDepartment of Family Medicine, University College Hospital, Ibadan, NGA.
Chinemerem D OnwuliriDepartment of Community Medicine, University of Nigeria Teaching Hospital, Enugu, NGA.
Adenekan OsiyemiDepartment of Family Medicine, University College Hospital, Ibadan, NGA.
Nnamdi UdeDepartment of Community Medicine, University of Nigeria Teaching Hospital, Enugu, NGA.
Amalachukwu A ChimeDepartment of Ophthalmology, University of Nigeria Teaching Hospital, Enugu, NGA.
Eric O OgborDepartment of Ophthalmology, Jos University Teaching Hospital, Jos, NGA.
Adegboyega O AlaoDepartment of Family Medicine, University College Hospital, Ibadan, NGA.
Ashiru AbdullahiDepartment of Ophthalmology, Federal Medical Centre, Katsina, NGA.
Federal Medical Centre · NGJos University Teaching Hospital · NGSeattle University · USFederal Medical Centre · NGKaduna State University · NGUniversity College Hospital, Ibadan · NG

Funding

Multidisciplinary NeuroAIDS Research Training to Improve HIV Outcomes in NigeriaD43TW009608 · FIC · NORTHWESTERN UNIVERSITY AT CHICAGO · PI PHILIP B GORELICK, Olayinka Olusola Omigbodun · 2013 to 2026
$3.9M
FIC NIH HHS D43 TW009608
6 · The paper itself

Abstract

backgroundThe coronavirus disease 2019 (COVID-19) pandemic heralded an unprecedented race to the development of several vaccine candidates at record speeds never seen in global health. Within nine months, Pfizer-BioNTech's COVID-19 vaccine was approved by the United States FDA. Unfortunately, while these advances were ongoing, there was a burgeoning epidemic of disinformation about the virus and the vaccines that affected the willingness of people, especially minority groups, to get vaccinated. In Nigeria, this wave of vaccine hesitancy was happening against the backdrop of landmark pharmaceutical litigations such as the 2007 Pfizer trovafloxacin lawsuit in the country.

aimTo assess the determinants of the COVID-19 vaccine's acceptability among Nigerians. MATERIALS AND

methodsFollowing ethical approval, a population-based cross-sectional study was conducted from November 2020 to January 2021 using an adapted pretested, self-administered questionnaire originally designed by Amyn Malik and colleagues who conducted a similar study at Yale University School of Public Health. The participants were recruited through simple random sampling using a list of community and corporate sites obtained from Google Maps in the three regional zones of Nigeria (north, east, and west) in diverse occupational and residential settings. Information obtained includes socio-demographics, medical history related to COVID-19, level of knowledge, risk perception, and attitudes toward COVID-19 and the vaccines. Descriptive and inferential statistics were done, and results were summarized into percentages and associations. The level of statistical significance was set at a p-value of <0.05. Using the open EpiR package (Emory), we determined a minimum of 340 participants for a statistical power of 80%.

resultsA total of 358 responses were obtained out of the 120 questionnaires distributed in each of the three regions, of which 189 (53%) were females. The mean age of respondents was 32 years (±11.2 SD). About 75% of the participants had at least a college education. The majority (66.2%) of the participants were willing to accept the approved vaccine. The mean risk perception score for COVID-19 was 5.1 (±2.2 SD) out of 10, while the mean COVID-19 symptom knowledge score was 8.6 (±4.1 SD) out of 19. Variables such as being male, identifying as Christian, Hausa ethnicity, and living in northern Nigeria had a statistically significant relationship with the willingness to get vaccinated.

conclusionOver 60% of Nigerians are willing to take the COVID-19 vaccines if recommended by health workers. We found male gender, religion, ethnicity, and geographical location to positively influence the willingness of Nigerians to get vaccinated against COVID-19. Health workers should be supported to go beyond the confines of the hospital to educate the general public in schools, marketplaces, churches, and corporate organizations on the efficacy and safety of the approved vaccines.

Indexed as

acceptanceadultscovid-19determinantsnigeria

Identifiers

PMID34963828
PMCPMC8695669
OpenAlexW4200200585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.